Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B.

Hamm R, Zeino M, Frewert S, Efferth T.

Toxicol Appl Pharmacol. 2014 Nov 15;281(1):78-86. doi: 10.1016/j.taap.2014.08.033. Epub 2014 Sep 11.

PMID:
25218289
2.

Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells.

Hamm R, Chen YR, Seo EJ, Zeino M, Wu CF, Müller R, Yang NS, Efferth T.

Biochem Pharmacol. 2014 Sep 1;91(1):18-30. doi: 10.1016/j.bcp.2014.06.018. Epub 2014 Jun 26.

PMID:
24976507
3.

Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B.

Hamm R, Sugimoto Y, Steinmetz H, Efferth T.

Invest New Drugs. 2014 Oct;32(5):893-903. doi: 10.1007/s10637-014-0134-1. Epub 2014 Jul 29.

PMID:
25065443
4.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.

5.

V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.

Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E.

Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14.

6.

The vacuolar-type ATPase inhibitor archazolid increases tumor cell adhesion to endothelial cells by accumulating extracellular collagen.

Luong B, Schwenk R, Bräutigam J, Müller R, Menche D, Bischoff I, Fürst R.

PLoS One. 2018 Sep 11;13(9):e0203053. doi: 10.1371/journal.pone.0203053. eCollection 2018.

7.

The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1.

Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, Wagner E, Müller R, Scita G, Vollmar AM.

Cancer Res. 2012 Nov 15;72(22):5976-87. doi: 10.1158/0008-5472.CAN-12-1772. Epub 2012 Sep 17.

8.

Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT.

Merk H, Messer P, Ardelt MA, Lamb DC, Zahler S, Müller R, Vollmar AM, Pachmayr J.

Mol Cancer Ther. 2017 Nov;16(11):2329-2339. doi: 10.1158/1535-7163.MCT-17-0129. Epub 2017 Aug 3.

9.

Targeting V-ATPase in primary human monocytes by archazolid potently represses the classical secretion of cytokines due to accumulation at the endoplasmic reticulum.

Scherer O, Steinmetz H, Kaether C, Weinigel C, Barz D, Kleinert H, Menche D, Müller R, Pergola C, Werz O.

Biochem Pharmacol. 2014 Oct 15;91(4):490-500. doi: 10.1016/j.bcp.2014.07.028. Epub 2014 Aug 12.

PMID:
25107704
10.

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2004 May 1;10(9):3216-24.

11.

Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.

Zhang S, Schneider LS, Vick B, Grunert M, Jeremias I, Menche D, Müller R, Vollmar AM, Liebl J.

Oncotarget. 2015 Dec 22;6(41):43508-28. doi: 10.18632/oncotarget.6180.

12.

Archazolid A-15-O-β-D-glucopyranoside and iso-archazolid B: potent V-ATPase inhibitory polyketides from the myxobacteria Cystobacter violaceus and Archangium gephyra.

Horstmann N, Essig S, Bockelmann S, Wieczorek H, Huss M, Sasse F, Menche D.

J Nat Prod. 2011 May 27;74(5):1100-5. doi: 10.1021/np200036v. Epub 2011 Apr 22.

PMID:
21513292
13.

RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.

Yeom SY, Nam DH, Park C.

Mol Cancer Ther. 2014 Dec;13(12):3049-61. doi: 10.1158/1535-7163.MCT-14-0244. Epub 2014 Oct 13.

14.

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.

15.

Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.

Stockhausen MT, Kristoffersen K, Stobbe L, Poulsen HS.

Cancer Biol Ther. 2014 Feb;15(2):216-24. doi: 10.4161/cbt.26736. Epub 2013 Nov 1.

16.

Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

Taylor TE, Furnari FB, Cavenee WK.

Curr Cancer Drug Targets. 2012 Mar;12(3):197-209. Review.

17.

Identification of differentially expressed proteins in human glioblastoma cell lines and tumors.

Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D.

Glia. 2003 Apr 15;42(2):194-208.

PMID:
12655603
18.

The EGFRvIII variant in glioblastoma multiforme.

Gan HK, Kaye AH, Luwor RB.

J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. Review.

PMID:
19324552
19.

Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.

Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L.

Cell Death Dis. 2015 Jan 15;6:e1601. doi: 10.1038/cddis.2014.566.

20.

Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.

Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.

Oncotarget. 2015 Nov 10;6(35):37570-87. doi: 10.18632/oncotarget.6066.

Supplemental Content

Support Center